依达拉奉右莰醇注射液治疗急性缺血性脑卒中的效果

Efficacy of Edaravone Dexbornol Injection in the Treatment of Acute Ischemic Stroke

目的探究依达拉奉右莰醇注射液治疗急性缺血性脑卒中(AIS)的临床效果及安全性。方法以2020年10至2022年2月郑州市第一人民医院收治的113例AIS患者(发病48 h内入院)为研究对象,采用随机数字表法分为常规组(56例)、研究组(57例)。常规组接受常规治疗,研究组加用依达拉奉右莰醇注射液静脉滴注。比较两组临床疗效、治疗前及治疗14 d后美国国立卫生研究院卒中量表(NIHSS)、Rankin修订量表(mRS)评分、大脑中动脉血流参数[平均血流速度(V_(m))、流速峰值(V_(s))、舒张末期流速(V_(d))]、血清超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、金属肽酶含血小板反应蛋白基元-1(ADAMTS-1)、Sestrin-2蛋白水平及不良反应发生率。结果研究组临床总有效率(94.74%)高于常规组(80.36%)(P<0.05);治疗14 d后,研究组NIHSS、mRS评分低于常规组(P<0.05);治疗14 d后,研究组V_(m)、V_(s)、V_(d)高于常规组(P<0.05);治疗14 d后,研究组血清hs-CRP、IL-1β、ADAMTS-1、Sestrin-2水平低于常规组(P<0.05);研究组不良反应发生率(8.77%)与常规组(5.36%)相比,差异无统计学意义(P>0.05)。结论依达拉奉右莰醇注射液辅助治疗AIS可有效抑制炎症因子表达,降低氧化应激反应,促进神经功能、脑循环改善,降低致残程度,提高日常生活能力,临床效果较好。

Objective To investigate the clinical efficacy and safety of edaravone dexbornol injection in the treatment of acute ischemic stroke(AIS).Methods A total of 113 patients with AIS admitted to Zhengzhou First People’s Hospital from October 2020 to February 2022(admitted to the hospital within 48 hours of onset)were selected as the research objects.They were divided into routine group(56 cases)and study group(57 cases)by random number table method.The routine group was given routine treatment,and the study group was additionally given edaravone dexbornol injection by intravenous drip.The clinical efficacy,National Institutes of Health stroke scale(NIHSS),modified Rankin scale(mRS)score,middle cerebral artery blood flow parameters[mean blood flow velocity(V_(m)),peak flow velocity(V_(s)),end-diastolic flow rate(V_(d))],serum high-sensitivity C-reactive protein(hs-CRP),interleukin-1β(IL-1β),a disintegrin-like and metalloproteinase with thrombospondin type 1motif(ADAMTS-1),the level of Sestrin-2 protein and the incidence of adverse reactions were compared between two groups.Results The total clinical effective rate of the study group was(94.74%)higher than that of the routine group(80.36%)(P<0.05).After 14 days of treatment,the NIHSS and mRS scores of the study group were lower than those of the routine group(P<0.05).After 14 days of treatment,the V_(m),V_(s) and V_(d) of the study group were higher than those of the routine group(P<0.05).After 14 days of treatment,the levels of serum hs-CRP,IL-1β,ADAMTS-1 and Sestrin-2 of the study group were lower than those of the routine group(P<0.05).The incidence of adverse reactions of the study group(8.77%)was not significantly different from that of the routine group(5.36%)(P>0.05).Conclusion The adjuvant edaravone dexbornol injection in the treatment of AIS can effectively inhibit the expression of inflammatory factors,reduce oxidative stress,promote the improvement of neurological function and cerebral circulation,reduce the degree of disability,and improve the ability of daily life,with higher clinical efficacy.